Oxylanthanum carbonate
Unicycive Therapeutics · hyperphosphatemia in chronic kidney disease patients on dialysisMar 25, 2027 target
Will the FDA approve Oxylanthanum carbonate for hyperphosphatemia in chronic kidney disease patients on dialysis?
Outcome claim / Research candidate
No market price yet.
This program has no funded pool or observed trading history. Start with the evidence, or explore a clearly labeled scenario.
This chart stays empty until observations exist. Research status is not an approval probability. A sandbox session creates a separate virtual price history.
Rx-UNCY-2703 / Evidence
UnlistedA pool price describes trading inventory; a model estimates an outcome. Neither a live price nor a dated forecast is available for this unlisted catalyst.
Program overview
Sponsor describes a nanoparticle oral phosphate binder and a March 25, 2027 target after NDA resubmission.
No reviewed probability or reasoning artifact is available. A neutral pool opening is not a clinical base rate.
What matters
- Prior CRLs and third-party manufacturing inspections make timing discontinuous; target may accelerate or slip.
- Approval, the stock price and commercial success are different outcomes. A claim only pays on its specified event.
- Future program funding and tokenized financing require separate rights and contracts. An event claim gives no equity, royalty or drug IP.